バイオ研究者・大学院生のための簡単な英語文例集その29
Trisha Gura HEMOPHILIA: After a Setback,
Gene Therapy Progresses ... Gingerly Science
2001 March 2; 291: 1692-1697. (in News Focus)
[Summary] [Full Text] |
最近の遺伝子治療の話題を紹介します。所々に私の解説(注)をつけます。お説教じみた老婆心的な記載も目立ちます。これがじゃまな人は、[Full Text]を読んでください。お説教の好きな奇特な方は私の注釈もご覧ください。(このページが想定している読者は?)
HEMOPHILIA:
After a Setback, Gene Therapy Progresses
... Gingerly
Trisha Gura*
Amid all the controversy and allegations
over gene therapy, clinical research is continuing,
and something close to a success story is
emerging
Katherine High and Mark Kay were on a roll.
Working independently, the researchers had
pulled off a scientific tour de force: In
January 1999, each reported using gene therapy
to partially correct hemophilia in dogs.
By April, the bicoastal duo--High is a hematologist
at Children's Hospital of Philadelphia and
Kay is a pediatric geneticist at Stanford
University--had joined forces and won approval
to test the new therapy in humans. In the
first stage of clinical trials, they injected
a novel gene into the leg muscles of three
hemophilia patients. The outcome proved better
than either had dared to hope: At a very
low dose designed to test safety, not efficacy,
the therapy did not harm patients and even
showed signs of alleviating disease symptoms.
The results, published in the March 2000
issue of Nature Genetics, brought a wellspring of hope to hemophilia
patients--of which there are 15,000 in the
United States alone--and a welcome tonic
for a field in which hype has far outstripped
payoffs.
Seemingly on their way to the gold, High's
and Kay's teams were preparing to up the
dose in the next trio of patients and seek
approval for a second trial that would inject
the novel gene directly into patients' livers.
But on 17 September 1999, the death of Jesse
Gelsinger in a gene therapy trial hit headlines--and
the field--with sobering force (Science, 17 December 1999, p. 2244). "We were worried," Kay recalls.
"We had no doubt that the field was
going to fall under a lot of scrutiny."
Many clinical trials were immediately put
on hold; others were cancelled outright.
Gelsinger's death, caused by the injection
of a novel gene construct into the young
man's liver, prompted a spate of investigations
that raised questions about everything from
the choice of vector to deliver the novel
gene, to ethical issues such as patient recruitment,
consent forms, and financial conflict of
interest. Overall, the tragedy forced the
research community into a collective soul
search. Although successes had been few and
far between, gene therapy practitioners had
assumed their research was safe--until now.
"It was a defining moment where people
began to say, 'Let's separate the wheat from
the chaff here,' " says Society for
Gene Therapy president Inder Verma of the
Salk Institute for Biological Studies in
La Jolla, California. Verma headed a special
meeting of the Recombinant DNA Advisory Committee
(RAC) in December 1999 to investigate the
Gelsinger case.
Katherine High: "It was such an obvious idea, transferring
genes from one organism to another. But as
we used to say in the lab, ideas are cheap."
CREDIT: BILL NATION
High and Kay voluntarily lowered the dose
they had planned to give the second cohort
of patients in the muscle trial. They also
postponed seeking approval for the liver
trial, which would inject the novel gene
into the hepatic artery--the same route of
administration used in the Gelsinger trial.
Since the incident, away from the public
glare, clinical work in the gene therapy
field has quietly continued. Indeed, some
of the most encouraging results to date,
High and Kay's included, have been reported
in this past year. In April 2000, for instance,
a group at the Pasteur Institute in Paris
published the first unequivocal results showing
that gene therapy can treat a rare immune
disease called severe combined immunodeficiency
(SCID) (Science, 28 April 2000, pp. 627, 669). Four months later, a team at M. D. Anderson
Cancer Center in Houston reported success
using gene therapy in combination with chemotherapy
to halt tumor growth in patients with head
and neck cancer. Most recently, a group at
the University of Pittsburgh used gene therapy
to repair a defect in mice with an ailment
that mimics Duchenne type muscular dystrophy.
But as High and Kay readily concede, the
field has been irrevocably changed by what
happened that day at the University of Pennsylvania
in Philadelphia and the stringent regulations
that have since emerged. "The final
rules are still not implemented," says
Kay. "But, depending on what happens,
clinical trials may become so difficult and
expensive that academic centers will not
be able to do them." The current environment
could deal a hefty blow to a field long plagued
by doubt--or simply mark its transition from
infancy to maturity.
A deceptively difficult task
High and Kay want to correct hemophilia by
giving patients a novel therapeutic gene
to make up for a defective one--in this case,
a gene that codes for a blood clotting factor.
The strategy seems straightforward: Bundle
the gene inside a modified virus and allow
that vector to ferry the gene inside the
patients' cells. Then, if all goes as planned,
the new gene will insert itself into the
cells' chromosomes. There, basic cell machinery
will switch on the corrective gene and produce
the much-needed clotting protein.
But, as High and Kay can attest after almost
a decade of trying, the feat is much more
elusive than it sounds. Like everybody else
in the field, they had to overcome a core--and
daunting--problem: how to get enough functioning
genes into target cells so they would make
sufficient quantities of protein, and how
to do so without triggering a severe immune
reaction. After numerous fits and starts,
High and Kay are now using a promising new
viral vector, but it still has limitations:
It can't yet carry the full-length gene needed
to correct one common form of hemophilia.
And overall, no gene therapy treatment has
yet reached the market for any disease. Through
the course of their studies, High and Kay
hooked up with a company that hopes to commercialize
their treatment, but such a product is years
away, they caution. In short, although High
and Kay are now considered two of the stars
of gene therapy, their decade-long struggle
shows just how tough life can be on this
new medical frontier.
Mark Kay: "I wasn't worried [from] the standpoint
of having a safety problem. I was more worried
about what the environment and the perception
might be."
CREDIT: BILL NATION
High, now director of research in the hematology
division at Children's Hospital, never expected
to end up pursuing gene therapy--or in the
middle of one of the most controversial fields
in medicine. In fact, she dreamed of working
as a bench chemist. But in the late 1970s,
she got hooked on medicine in general and
hemophilia in particular during a stint with
pathologist and coagulation expert Kenneth
Brinkhous and his famed blood coagulation
group at the University of North Carolina,
Chapel Hill.
The group's main focus was hemophilia, an
X chromosome-linked disease that afflicts
about 1 in every 5000 people, mostly males.
The disease is characterized by the lack
of at least one of a family of key enzymes
that aid in blood clotting. Two of the most
prominent are called Factor VIII, which is
the culprit in hemophilia A, and Factor IX,
which when defective causes hemophilia B,
the less prevalent of the two disease forms.
The sickest patients suffer uncontrollable
bleeding episodes and debilitating joint
damage.
Then, as now, clinicians had few treatment
options for hemophilia: mainly giving patients
injectable concentrates of a clotting factor
derived from blood plasma (now, by recombinant
means); or, in developing countries, where
most hemophiliacs don't live beyond their
20s, simple bed rest and ice. Patients with
a severe form of the disease--defined as
making less than 1% of the normal amount
of either clotting factor--have to inject
themselves with blood factor proteins up
to three times a week at a cost approaching
$100,000 a year. Such injections promote
clotting and temporarily relieve joint pain,
but they have had ugly consequences: More
than 90% of adult hemophiliacs are now infected
with hepatitis C or HIV from contaminated
blood products. Patients with a more moderate
form of the disease--defined as having 1%
to 5% of normal levels of the enzyme--live
a significantly easier life with far fewer
injections.
Thus, the Holy Grail for any hemophilia gene
therapist is to boost the active level of
enzymes above the benchmark 1%. That fairly
lax requirement is one reason why a handful
of intrepid researchers venturing into gene
therapy in the early 1990s picked hemophilia
as their target. Another reason is that the
protein can make its way into the bloodstream,
where it is needed, when the gene is expressed
in any one of a multitude of cell types,
unlike, say, cystic fibrosis, in which the
gene must be expressed in the lungs or surrounding
tissue.
But first investigators had to find and characterize
the human genes for Factor VIII and Factor
IX--a feat pulled off by researchers including
George Brownlee and colleagues at Oxford
University in the mid-1980s and Darrel Stafford
at Chapel Hill. Hemophilia researchers, including
High, spent the next 5 years determining
how defects in those genes influence disease
severity. "This was a fertile time for
expressing clotting factors and getting large
amounts of them to study," High recalls.
Specifically, High studied how alterations
in the structure of the protein affect its
function as a blood clotting enzyme. But
her group needed animal models in which they
could better study the disease and its treatments.
So in 1989, High and postdoc Jim Evans identified,
cloned, and characterized the Factor IX gene
defect that causes hemophilia B in a colony
of dogs born with the illness. Canines are
the animal model of choice because of their
size and similarity to humans. But dogs are
expensive to house and relatively hard to
work with. To create a more malleable mouse
model, three groups led by Stafford at Chapel
Hill, Verma at Salk, and Erlinda Maria Gordon
at the University of Southern California
in Los Angeles, knocked out the gene for
Factor IX in a strain of mice in the early
1990s. Haig Kazazian, currently chair of
genetics at Penn, did the same for Factor
VIII. With this work, hemophilia researchers
had a gamut of organisms to work with, from
cells to rodents to dogs. "It is a model
that a lot of gene therapy ought to copy,
if it could," says gene therapist Savio
Woo of Mount Sinai School of Medicine in
New York City.
Early in 1991, High and colleagues decided
to take the plunge into gene therapy. "It
was such an obvious idea, transferring genes
from one organism to another," High
explains. "But as we used to say in
the lab, ideas are cheap." And often
they don't work, High soon found out. When
trying gene transfer experiments in animals,
her Chapel Hill team quickly ran into the
roadblocks that had stymied other fledgling
gene therapists: namely, the vectors. For
years, researchers could not coax the contemporary
virus vectors to shuttle Factor IX genes
into cells in culture. One popular vector
of the day, retroviruses, didn't deliver
enough genes into cells to eke out even 1%
of normal Factor IX levels. The other available
vector, adenoviruses, had its own drawbacks,
chief among them that the immune system easily
recognizes the virus vector, which in its
unaltered state causes the common cold. Host
cells harboring adenoviruses and their corrective
genes are quickly pitched out of the body.
On a national front, meanwhile, gene therapy
was gaining credibility. After lengthy debates
on safety and ethical issues, W. French Anderson,
then at the National Institutes of Health
(NIH), and colleagues in 1990 had won approval
from the RAC to conduct the first human gene
therapy trial in the United States. In September,
with reporters and photographers on hand
to record the event, Anderson and his colleagues
injected a corrective gene into a 4-year-old
girl with SCID. Trials to treat various cancers
followed 5 months later.
A new vector offers hope
A year after Anderson's pioneering experiment,
High moved to Penn, where she could devote
herself entirely to lab work. She set up
shop in the pediatrics department of the
affiliated Children's Hospital. At Penn,
officials were aggressively building the
Institute for Human Gene Therapy, now the
largest in the country. James Wilson, who
later led the team of doctors that treated
Gelsinger, was hired in 1993 to head it.
Signs of success. In clinical trials, High and Kay injected
adeno-associated virus carrying a corrective
gene for hemophilia into the leg muscles
of several patients. As hoped, the cell's
machinery switched on the gene that codes
for blood clotting factor IX. Fibers expressing
the clotting factor appear green.
CREDIT: MARK A. KAY AND ROLAND W. HERZOG/THE
CHILDREN'S HOSPITAL OF PHILADELPHIA AND UNIVERSITY
OF PENNSYLVANIA MEDICAL CENTER
About the time High made her move, a hot
new virus vector, known as adeno- associated
virus or AAV, made its debut. High and many
others were right on it-- including Kay on
the other side of the country. First developed
and patented for use as a biological vector
by virologists Barry Carter, then at NIH,
and Nicholas Muzyczka of the University of
Florida, Gainesville, the novel vector looked
like the much-needed shot in the arm for
the disheartened field. The vector, in essence,
is a core of viral DNA shrouded in a protein
coat. Related to adenovirus in name only,
AAV doesn't cause any disease in humans or
other mammals. The virus simply enters cells
and homes in on chromosome 19. There, the
strand of viral DNA inserts itself and becomes
a permanent part of the host cell's chromosome.
Given this mode of integration, researchers
hoped that this new vector, unlike adenovirus,
might be able to avoid detection and annihilation
by the host immune system. What's more, it
seemed to be able to target nonreproducing
cells. But again, there were problems. Many
researchers soon found that they could not
coax the virus to grow in culture in the
lab. Nor could they shoehorn large genes,
such as Factor VIII, into the viral capsule.
And once loaded with smaller corrective genes,
the virus no longer integrated into its predictable
spot on chromosome 19 but inserted randomly
throughout the genome.
A few found their way around these problems.
One was viral guru Jude Samulski, now at
Chapel Hill, who in the early 1990s pioneered
the use of AAV as a gene-delivery vehicle.
Samulski encouraged High and supplied her
with the biological materials she needed
to make the crucial vectors. With Samulski's
help, High succeeded in splicing the gene
for Factor IX, which is shorter than that
for Factor VIII, into AAV.
In key experiments in 1997, High and postdoc
Roland Herzog teamed up with Wilson. The
team injected AAV carrying human Factor IX
genes into the leg muscles of mice; after
the gene integrated into muscle cell chromosomes,
the rodents steadily and stably churned out
therapeutic levels of Factor IX. The following
year, High was able to use AAV, loaded with
human Factor IX, to correct hemophilia in
Stafford's genetically altered mice by injections
into either rodents' leg muscles or livers.
Finally in January 1999, High, Herzog, and
Tim Nichols, also of Chapel Hill, reported
in Nature Medicine that they had partially corrected hemophilia
B in a dog colony. To do so, they injected
AAV, laden with canine Factor IX, into the
animals' leg muscles. The paper ran back
to back with an equally eye-catching report.
Kay's group at Stanford, in collaboration
with Richard Snyder, then at Somatix Therapy
Corp. in Alameda, California (now owned by
Cell Genysis), had independently engineered
its own version of AAV carrying the gene
for Factor IX. The West Coast team had pumped
the vector directly into liver veins of hemophiliac
mice and dogs obtained from Nichols. The
liver procedure, although more invasive and
therefore more risky than muscle injection,
proved to be slightly more efficacious. In
both procedures, the treated dogs produced
at least 1% of normal blood levels of Factor
IX. Kay's liver protocol, however, needed
10-fold fewer viruses to do the trick, in
part because of stronger liver-specific promoters
that drive the gene harder.
"These were very promising studies,"
says Anderson, who notes that at that time,
no one had achieved such high levels of expression
by injecting a new gene directly into muscle
tissue.
From competition to collaboration
Unlike High, hemophilia wasn't even Kay's
area of expertise--it was gene therapy instead
that drew him into the field. As an M.D.-Ph.D.
student at Case Western Reserve University
in Cleveland in the early 1980s, Kay was
struck by the potential of this budding field.
Admittedly naive, Kay initially feared the
field would pass him by. The concept seemed
so simple, "I figured by the time I'd
finished medical school, residency, and my
fellowship, all the interesting diseases
would already be cured," he recalls.
That was hardly the case. By the time Kay
graduated from Case in 1987, Anderson and
other gene therapy pioneers were still wrestling
with uncooperative vectors and tough regulatory
hurdles that seemed to be getting tougher,
as members of the RAC battled with Anderson
and each other. Kay got his chance to witness
gene therapy experiments firsthand in 1989,
when he moved to Baylor College of Medicine
in Houston, Texas. As he completed his pediatric
genetics residency in the clinic, he also
worked at the bench with molecular biologist
Woo, who was then beginning to dabble in
gene therapy.
Kay wanted to use those nascent tools to
help the children he saw in the clinic, most
of whom were stricken with so-called inborn
errors of metabolism. These diseases often
involve rare genetic defects in various crucial
liver enzymes--defects that cause devastating,
if not fatal, consequences. "We could
make the diagnoses, but we were really horrible
at trying to develop efficacious therapy,"
Kay recalls. "I realized that the chances
of treating these diseases with anything
other than gene therapy [were] pretty low."
Kay started working on hemophilia in the
hope that any gene therapy techniques he
devised could later be used for other liver-based
disorders. By the end of his Baylor stint,
Kay had been able to partially correct the
defect in hemophiliac dogs using a retrovirus
that carried Factor IX. But the procedure
itself was draconian and "not something
that you could do to people on a wide scale,"
says Kay. Because retroviruses can only target
dividing cells, injecting the vector directly
into the body failed to get anything more
than a negligible amount of corrective genes
into liver cells. Kay's team had to remove
two-thirds of an animal's liver, prod the
cells to divide in culture, and then infuse
the retrovirus vector carrying the Factor
IX gene into the vein that runs into the
liver.
Despite the clinical impracticality, Kay
published his work in 1993 as a "proof
of principle" (Science, 1 October 1993, p. 29). Such obstacles
gave Kay pause, however. "You solved
one problem, and then you'd get another you
did not anticipate," Kay recalls. "I
really thought hard about whether I should
work on gene therapy."
注: うちの大学院生やポスドクたちの中にも、仕事を始めてしばらくすると、「遺伝子治療の分野はもう盛りを過ぎて衰退していくだろう。ここでやっている遺伝子治療の仕事はどんどん発展してついに臨床までいくようになるなんて思えない。少なくとも、自分で進めるのは無理だ。手っ取り早く適当に仕事をまとめて終わりにして、また他の分野の研究をやっている他の研究室に移りたい。」というような悲観的な弱気な意見を述べる人がでてきます。この弱気に他の大学院生たちが引っ張られなければよいのですが。株式市場の用語を使うなら、bearな見方をする研究者です。(注の注: bearとは熊さんのこと。右肩下がりの弱気・悲観曲線です。反対はbull、雄牛です。右肩上がりの強気・楽観曲線。)どのくらい長期に投資的な研究を続けるガッツを持つかで、「遺伝子治療の分野」もbearだったり、bullだったりするわけです。hype(ハイプ)だけでbearishな若い研究者を引き留めておくことは、私の研究室のような基礎講座では容易なことではありません。根本は、頭じゃなくて、情熱でしょうか。
At the same time, Kay and other gene therapists
were confronting an increasingly skeptical
research community. After repeated failures
and slow progress, a 1995 report commissioned
by then-NIH director Harold Varmus essentially
warned the community to turn down the hype.
注: hype(ハイプ)というのは、大げさな売り込み、誇大広告という意味です。アメリカの科学雑誌のニュース欄には盛んにこの単語が出てきます。
turn down the hype でおおげさな広告は退けろ、ということになります。
Kay decided to stick with gene therapy, lightening
his patient load and devoting most of his
time to looking for other vectors and strategies
to improve gene transfer into human cells.
注: 「遺伝子治療」には執着しつづけ、でも、いろいろなベクターとストラテジーを探すのに集中した。これです。これが研究というものです。(ただし、最後まで失敗しつづけた研究者はScienceに載りません。あしからず)
"I realized that to be effective, I
couldn't be doing a little bit of everything,"
says Kay, who by 1993 had moved to the University
of Washington, Seattle. Kay's move came on
the heels of High's relocation to Penn. And
like High, Kay soon began working with AAV,
trying to engineer a construct to treat hemophilia
in a mouse model. Because of his bent toward
liver diseases, Kay worked on liver routes
of delivery instead of methods with muscle
cells, enlisting the help of Snyder at Somatix
to provide him with a steady supply of AAV.
Almost a decade of effort paid off in 1997,
when Kay and colleagues reported in Nature Genetics that they had provided normal mice with
curative levels of human Factor IX via one
injection of genetically altered AAV into
the rodents' liver veins. Only then, says
Kay, did "I realize that gene therapy
really would work in people."
Kay and postdoc Hiroyuki Nakai spent the
next 2 years trying to extend this work to
dogs. In January 1999, as "friendly
competitors," Kay and High published
their dueling Nature Medicine papers showing the partial correction of
hemophilia (up to 1% of normal protein levels)
in dogs. The feat placed them well ahead
of their colleagues and competitors such
as Salk's Verma, who in 1998 also used AAV--injected
into the liver--to correct hemophilia in
mice lacking Factor IX. "Up until this
point, [corrective] Factor IX genes could
be expressed but not enough to make therapeutic
amounts of protein," Verma says.
Royal blood. Queen Victoria's family was plagued by hemophilia,
an X chromosome-linked disease that affects
mostly males.
CREDIT: COURTESY OF KATHERINE HIGH
Kay and High, who often sat together trading
notes at NIH meetings on hemophilia gene
therapy, soon decided to collaborate and
move the work into humans, fusing her expertise
in hemophilia with Kay's flair for manipulating
vectors--a winning combination, says Anderson.
High recalls saying to herself, "Well,
I could stay funded for the next 20 years
just doing mouse and dog experiments, and
it would be a lot less grief for me. But
sooner or later I have to ask, 'Is this going
to work in people?' "
注: この文章、覚えておきましょう。But sooner
or later I have to ask, 'Is this going to
work in people?' われわれ治療の研究者は、いつもこのセンテンスを忘れないようにしましょう。Is
this going to work in people?です。卒業したのが医学部じゃないから臨床研究は関係ない、という言い方をする大学院生にもよくお目にかかります。これは間違っています。治療の研究をする限り、対象は常にヒトを見据えています。出身学部や免許を持っているかどうかなどは、全然関係ないことです。
Into humans
The deal was set. High would take the lead
on delivering the corrective gene via muscles
--and write up the necessary documents for
Food and Drug Administration (FDA) approval
in that tissue--while Kay would do the same
for liver approaches. Avigen, a biotech company
in Alameda, California, that High had been
working with, would make the AAV vectors
for both and help fund the trials. In this
arrangement, the researchers sit on Avigen's
scientific advisory board and are compensated
for their time and expertise. To avoid the
appearance of any conflict of interest, the
two do not directly participate in recruiting
patients, gaining informed consent, or treating
patients in the trials. The regulatory bodies
bought it. By April 1999, the pair passed
through biosafety committee and internal
review by boards at both Stanford, where
Kay is now director of the program in human
gene therapy, and Children's Hospital; initial
review by the RAC; and then ultimate approval
by the FDA for safety trials.
Kay and High thought the biggest risk lay
in a quirk of hemophilia. Individuals with
certain forms of hemophilia--the type caused
by large deletions of genetic material as
opposed to simple misspelled nucleotides
--do not produce any clotting factors at
all; thus, the immune system has not had
a chance to develop a "tolerance"
to the otherwise native proteins. High and
Kay worried that if they successfully introduced
a gene for the clotting factor into patients
with large gene deletions, thereby providing
them with a steady supply of protein, the
patients' immune systems might consider the
protein to be foreign and make antibodies
to destroy it. Not only would gene therapy
be unsuccessful, but patients' lives might
be endangered if, during a later bleeding
episode, they produced antibodies to the
clotting enzymes administered to save them.
For these and other safety reasons, Kay and
High decided to start with muscle instead
of liver injections. Even though AAV takes
6 to 12 weeks to settle into a nesting site
within the cell nucleus, the gene usually
does not stray far from the site of injection
--in other words, if the vector were injected
into the muscle, it would stay there. "If
you have some unanticipated untoward effect,
you can go back and resect the muscle,"
High notes. "Once you go into the liver,
that's it. You are there."
To hedge their bets further, High and Kay
selected only patients with misspelling mutations.
Those may cause the gene to produce a faulty
blood clotting protein, but a protein nonetheless.
That meant that all patients in the trial
would likely have been exposed to inactive
blood clotting factors. The duo won FDA approval
for their muscle trial--the first gene therapy
trial ever to inject AAV.
High watched anxiously from the side of the
treatment room in June 1999, when hematologist
Catherine Manno, who led the clinical team
at Children's Hospital, injected the first
patient with genetically altered AAV. To
their relief, the procedure went without
a hitch. As the team reported in the March
2000 issue of Nature Genetics, at the initial, suboptimal dose meant only
to detect obvious safety problems, the first
three patients, aged 23 through 67, showed
no apparent toxicity. Even more encouraging,
within 12 weeks after the injection, the
team detected normal Factor IX genes--and
the actual protein itself--in biopsies taken
from the patients' legs. That meant that
the gene had been incorporated into muscle
cells and then produced its protein. The
presence of Factor IX in the bloodstream
suggested that the protein had successfully
crossed from tissue to its target destination.
To date, none of the three patients has produced
any antibodies to fight off the protein.
What's more, High and Kay reported, patients
fared even better than animal studies would
have predicted: Even at low doses, one of
the three patients showed a boost in circulating
levels of Factor IX--one even topped the
benchmark 1%. Two of the three patients also
reported needing significantly fewer therapeutic
protein injections to treat and prevent bleeding
episodes.
To Anderson, now at the University of Southern
California, the results were "not a
matter of excitement, but a matter of relief."
If gene therapy doesn't work for hemophilia,
he says, it is unlikely to succeed for most
other diseases. An ever-cautious High will
only say she was "surprised and pleased"
at the apparent, although preliminary, success.
Although the early results appear positive,
Salk's Verma also warns against overoptimism.
Because the patients in the study did not
yet make enough protein to cure their disease,
they also did not make enough to test whether
the added protein will trigger the production
of anti-Factor IX antibodies. "It's
a double-edged sword," says Verma.
The Gelsinger case
Buoyed by their preliminary success, High
and Kay moved to collect more data. But,
just as the team was getting ready to inject
the next three patients with a slightly higher
dose and to propose a second trial, Jesse
Gelsinger died. The news hit hard. The young
man was being treated for an entirely different
disease: a deficiency in a liver enzyme called
ornithine transcarbamylase that's needed
to remove ammonia from the blood. The Penn
team was also using a different vector--adenovirus--one
that Kay and High had abandoned. But there
was one similarity: High and Kay were proposing
to introduce their more benign vector via
the exact same entry route that the Penn
team had used: direct infusion into the main
liver artery.
Under scrutiny. The death of Jesse Gelsinger in a gene therapy
trial at the University of Pennsylvania prompted
a spate of investigations and hearings, including
the December 1999 RAC meeting where James
Wilson, head of Penn's Institute for Human
Gene Therapy, testified.
CREDIT: SAM KITTNER
FDA soon halted all trials at Penn's Institute
for Human Gene Therapy and stopped several
other human studies using adenovirus vectors
(as opposed to AAV). Although High and Kay's
trial was not directly affected, all gene
therapy fell under intense scrutiny.
Without any prodding, High and Kay immediately
began to review their animal and human data
to decide how or whether to go forward. "I
think it is really important, number one,
that safety issues are addressed," says
Kay. "There has been some debate by
members of the gene therapy community that
if the rules had been followed previously,
this might not have happened," he says,
referring to the death at Penn.
The pair decided to lower the next dosing
regimen to a half-log increment and sent
a letter to the FDA requesting permission
to modify their trial. Kay and High had also
planned to present their proposed liver trial
to the RAC for discussion at its December
1999 meeting but postponed the review until
the following March. "I wasn't worried
[from] the standpoint of having a safety
problem," Kay says. "I was more
worried about what the environment and the
perception would be."
It proved to be a wise decision. At a packed
2-day meeting conducted under the glare of
television cameras, it became clear that
both the adenovirus vector and the route
of administration were suspect. Scrutiny
continued at the next RAC meeting on 9 March,
when Kay and Bert Glader, the Stanford physician
who would head the clinical trials, presented
their proposal to use AAV, injected into
the liver artery, to carry a corrective gene
into hemophilia patients. It passed muster.
The RAC approved the proposal, and the trial
now sits before the FDA awaiting the ultimate
nod.
As the researchers wait, the muscle trial
continues. On the advice of FDA, Manno has
amended the consent form for clinical trials
to mention the Gelsinger death and the risks
of gene therapy. The middose crop of patients
is doing well, Kay and High reported at an
American Society of Hematology meeting in
San Francisco in November 2000. One patient
achieved the 1% benchmark and reported a
reduction in self- administration of clotting
factor. The other two, however, did not reach
that benchmark. "We're still looking
for a dose where every subject gets a result
over 1%," says High. The team recently
increased the dose by another half-log in
three more patients.
High and Kay will likely have to meet even
more stringent requirements in the liver
trial. Over the past year, the RAC proposed
new reporting and monitoring requirements
to enable them to track adverse events. Among
other things, these rules call for an independent
monitor to check that data are being collected
and reported properly. Hiring such an expert
can add $100,000 to the already hefty price
of clinical trials. Kay says that every day
he spends an increasing amount of time complying
with these rules and worries about the effect
of such costs and paperwork on the field.
Despite the expense, however, the pharmaceutically
minded are convinced the investment will
payoff. Avigen announced in November that
it had entered a partnership with pharmaceutical
giant Bayer Corp., headquartered in Leverkusen,
Germany. Bayer, with a long interest in hemophilia
drugs, plunked down $60 million to help conduct
and finance phase II and phase III clinical
trials with Avigen's Factor IX-laden AAV
vector, dubbed Coagulin-B. In exchange, Bayer
will hold regulatory licenses of the drug
worldwide and receive royalties from its
sales.
Both High and Kay say the Gelsinger tragedy
has changed their working lives. "At
this point, the field is not something to
go into if you want to labor in obscurity,"
High remarks. "It's a highly visible
field because of public, commercial, and
political interest. That creates a great
deal of pressure."
But, having spent years treating patients,
they also believe the potential payoff is
well worth the pressure. Indeed, Kay remains
as optimistic as he was in medical school.
Says Kay: "We are starting to see evidence
of success and to really appreciate the potential
of gene therapy for the entire field of medicine."
Trisha Gura is a science writer in Cleveland,
Ohio
バイオ研究者のための英語 目次へ
|